Vapotherm, Inc. (VAPO)
| Market Cap | 740.68M |
| Revenue (ttm) | 124.40M |
| Net Income (ttm) | -57.30M |
| Shares Out | 25.89M |
| EPS (ttm) | -2.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,312 |
| Open | 28.20 |
| Previous Close | 28.48 |
| Day's Range | 27.26 - 28.73 |
| 52-Week Range | 16.64 - 38.46 |
| Beta | -1.59 |
| Analysts | Strong Buy |
| Price Target | 41.50 (+51.1%) |
| Est. Earnings Date | Nov 3, 2021 |
About VAPO
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companio...
Financial Performance
In 2020, Vapotherm's revenue was $125.73 million, an increase of 161.38% compared to the previous year's $48.10 million. Losses were -$51.50 million, 0.87% more than in 2019.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for Vapotherm stock is "Strong Buy." The 12-month stock price forecast is 41.50, which is an increase of 51.13% from the latest price.
News
Vapotherm Raises Annual Sales Outlook Amid Surge In COVID-19 Cases
Vapotherm Inc (NYSE: VAPO) expects FY21 revenue of at least $102 million, an increase of $17 million over the low end of previous guidance of $85 million - $91 million. Related Content: FDA Gives 510(...
Vapotherm Increases Fiscal Year 2021 Revenue Outlook and Announces Expansion of Production Capacity
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), today updated its fiscal year 2021 revenue expectations and announced it will expand its disposables productio...
FDA Gives 510(K) Nod To Vapotherm's Next-Gen High-Velocity Therapy
The FDA has granted 510(k) clearance to Vapotherm Inc's (NYSE:VAPO) HVT (high-velocity therapy) 2.0. Vapotherm high-velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool...
Vapotherm Announces FDA 510(k) Clearance for HVT 2.0 Next Generation Platform
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced it has received 510(k) clearance from the US Food and Drug Administration for HVT 2.0. This n...
Vapotherm (VAPO) Reports Q2 Loss, Tops Revenue Estimates
Vapotherm (VAPO) delivered earnings and revenue surprises of -4.69% and 13.45%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Vapotherm Reports Second Quarter 2021 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Analysts Estimate Vapotherm (VAPO) to Report a Decline in Earnings: What to Look Out for
Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vapotherm to Participate in the Canaccord Genuity 41st Annual Growth Conference
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Vapotherm to Report Second Quarter 2021 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapoth...
Vapotherm to Host First Investor Day
EXETER, N.H,--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Vapotherm to Participate in the William Blair 41st Annual Growth Stock Conference
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Vapotherm to Participate in the Bank of America Securities 2021 Health Care Conference
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Vapotherm (VAPO) Reports Q1 Loss, Tops Revenue Estimates
Vapotherm (VAPO) delivered earnings and revenue surprises of 2.44% and 2.31%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Vapotherm Reports First Quarter 2021 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Will Vapotherm (VAPO) Report Negative Earnings Next Week? What You Should Know
Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vapotherm to Report First Quarter 2021 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapoth...
Vapotherm (VAPO) Reports Q4 Loss, Tops Revenue Estimates
Vapotherm (VAPO) delivered earnings and revenue surprises of 10.53% and 0.82%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Vapotherm Reports Fourth Quarter and Fiscal Year 2020 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Vapotherm to Participate in Fireside Chat at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic To...
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Vapotherm to Report Fourth Quarter and Fiscal Year 2020 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Vapotherm Reports Preliminary Fourth Quarter and Fiscal Year 2020 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Vapotherm to Present at the 23rd Annual ICR/Westwicke Conference
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Vapotherm Wins Prestigious Zenith Award from American Association for Respiratory Care for Support of Respiratory The...
EXETER, N.H.--(BUSINESS WIRE)---- $VAPO--Vapotherm, Inc. (NYSE:VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its propriet...
Vapotherm Updates Its Fourth Quarter and Fiscal Year 2020 Outlook
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Vapotherm: The Game Has Completely Changed
Vapotherm's Hi-VNI technology is more comfortable and safer than current technologies used to treat patients with respiratory distress. The company has seen meaningful sales increases over the past two ...